Mental Health Assessment and Prescribing by Alberta Pharmacists

Summary

This is a clinical trial evaluating the experimental intervention of enhanced pharmacist care by pharmacists with additional prescribing authorization (APA) in Alberta, for patients newly diagnosed with Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD).

Conditions

• Major Depressive Disorder
• Generalized Anxiety Disorder
• Pharmacist-Patient Relations

Interventions

OTHER

Standard Pharmacist Care

Standard pharmacy care (as outlined in the Alberta College of Pharmacist Standards of Practice for Pharmacist and Pharmacy technicians)

OTHER

Reviewed Questionnaire tool results with participant

Pharmacist reviews results of the patient-administered PHQ-9 and/or GAD-7 questionnaire tool, at the scheduled follow-up appointment

OTHER

Patient Clinical Assessment

Pharmacist conducts clinical assessment of the participant's major depressive disorder and/or generalized anxiety, which can include: appearance, current mood, sleeping patterns, mental health, medical history, social history, family history, relationship with others, suicidal ideation, previous suicide attempts or hospitalizations, current employment status

OTHER

Psychotherapy Referral

Pharmacist initiates collaboration with physician to arrange referral for psychotherapy, including: psychologist, social worker, counsellor, psychiatrist

OTHER

Pharmacist initiated interim telephone follow-up with participant

Interim telephone follow-up conducted by the pharmacist since the last in-person follow-up \& a minimum of 1-2 weeks after the last in-person follow-up that involved a dose adjustment, prescribing of adjunctive medication, or discontinuation of therapy (Note: a telephone follow-up does not replace the scheduled in-person follow-up)

OTHER

Communication update with physician after participant contact

Pharmacist provides communication update (fax or electronic charting) with the participant's physician after contact with the participant

OTHER

Medication Counselling and Educational Support

Pharmacist provides medication related counselling and educational support to participant

OTHER

Non-medication Counselling

Pharmacist provides non-medication related counselling and educational support to participant

OTHER

Identification of drug interaction

Pharmacist identification of drug interaction related to medication for major depressive disorder and/or generalized anxiety

OTHER

Identification of drug adverse effect

Pharmacist identification of adverse effect related to medication for major depressive disorder and/or generalized anxiety

OTHER

Identification of severe deterioration

Pharmacist identification of participant severe deterioration (i.e. suicide attempt)

OTHER

Pharmacist-to-physician recommendation for medication adjustment, change to alternative, add-on, or deprescribing

Pharmacist collaborates, discusses, and makes recommendations to physician re: treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing

OTHER

Pharmacist initiated medication adjustment, change to alternative, add-on, or deprescribing

Pharmacist initiated alteration to treatment plan for MDD and/or GAD (as per CANMAT guidelines), which can include: medication dose adjustment, change to alternative medication, add-on, or deprescribing

Sponsors & Collaborators

• University of Alberta

  lead OTHER

Principal Investigators

• Yazid Al Hamarneh, BSc (Pharm), PhD, CDM · University of Alberta

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2023-03-22

Primary Completion

2025-03-31

Completion

2025-05-31

Countries

• Canada

Study Locations